Abnormal uterine bleeding (AUB) is the name given to describe any deviation from the normal menstrual cycle. The average cycle lasts 29 days with a range of 23-39 days with bleeding episodes lasting 2-7 days. The International Federation of Gynecology and Obstetrics (FIGO) and the American Congress of Obstetricians-Gynecologist have endorsed the PALM-COEIN classification system that divides AUB into structural and non-structural causes. The PALM-COEIN table is available for review under the etiology section of this paper and has led to the terms menorrhagia (prolonged or excessive bleeding), oligomenorrhea (bleeding greater than 35 days), intermenstrual bleeding (bleeding between cycles), and postmenopausal bleeding to fall out of favor. This paper will discuss the aspects of acute AUB in non-pregnant reproductive-age women when it is of sufficient quantity to require prompt intervention to prevent further blood loss.
Menorrhagia, or abnormal uterine bleeding (which is the preferred terminology), can be classified into nine categories making up the PALM-COEIN acronym. This table divides AUB into structural and non-structural causes:
It is essential for the provider to choose the most likely etiology for the effective and appropriate management of these women.
Abnormal uterine bleeding, or menorrhagia as previously classified, is a predominant complication among women in the United States that is related to the major impacts of women's quality of life, productivity, and healthcare cost. Reports are that the annual prevalence rate is 53 per 1000 women. In the outpatient setting, AUB is one of the leading causes of outpatient gynecological visits with 20-30% of women presenting with this complaint annually.
The pathophysiology of abnormal uterine bleeding (AUB) is as diverse as the classification of the disease. AUB can be caused by pelvic pathology like a distortion of the endometrial cavity due to fibroids, or endometrial protrusions into the cervix or vagina (polyps), or because of friable endometrial tissue. The friable endometrial tissue is likely caused by unopposed estrogen which causes the endometrium to become friable, vascular, and lacking sufficient stromal support which equates to heavy, continuous uterine bleeding.
Systemic conditions are also responsible for AUB. Obesity is an epidemic whose consequences affect every aspect of life and every organ system. In women, obesity can lead to unopposed estrogen and can lead to polycystic ovarian syndrome. Coagulopathies can also lead to AUB; 13% of women with AUB have a variant of Von Willebrand disease, and 20% have an underlying coagulopathy.
Another important consideration and a significant cause of AUB are the patient’s medications. An intact coagulation pathway is essential for menstrual regulation and medications that interact with platelets and coagulation factors can lead to Acute AUB. The following is a list of some medications that can lead to AUB:
Obtaining a complete history and physical, focused on questions directed towards PALM-COEIN etiologies will allow the provider to narrow the likely etiologies. It is important for the clinician to gain a complete understanding of the current bleeding episode, a history of her menstrual cycles, gynecological and obstetrical histories, medical and surgical history, current medications, sexual history, and family history. Women who report changing pads/tampons every 3 hours and report clots are likely to have a blood loss of at least 80mL. As mentioned previously, a large percentage of women who present with acute AUB will have some form coagulopathy, with von Willebrand disease being the most common.
To evaluate the history of bleeding disorders, there is an already established clinical screening tool to assist the provider in determining if the patient will benefit from further coagulopathy testing. A positive screening, includes the following:
The physical exam should initially be aimed at assessing life-threatening conditions caused by the acute blood loss, anemia, and hypovolemia. It is also essential to confirm the cause of the acute uterine bleeding. A speculum exam should be performed to thoroughly investigate the genital tract to rule out trauma or other etiologies of bleeding. A bimanual exam will also be essential to evaluate for uterine abnormalities and enlargement caused by leiomyomas, or cervical abnormalities caused by polyps or cervical cancer.
Laboratory evaluation of the patient is essential in guiding the treatment and management of the patient. The initial labs on every patient include complete blood count, blood type and crossmatch, and a pregnancy test. Additional important tests for guiding care for the patient include thyroid-stimulating hormone, iron studies, liver function test, and sexually transmitted disease testing. If the clinical suspicion of coagulopathy is present, it would also the recommendation is that testing for von Willebrand disease and initial coagulopathy labs be performed.
With respect to treatment and management, the initial goal is to stabilize the patient’s hemodynamics. If the patient is unstable, the patient should have two large bore IVs, airway assessment, and have a type and cross in preparation for blood transfusion. For the unstable patient before surgical interventions, intrauterine tamponade should be performed. A Bakri balloon can be inserted into the uterus to tamponade uterine bleeding. If an intrauterine balloon is not available, gauze packing is an acceptable option. The physician should use a continuous piece to eliminate the risk of retained products. If the bleeding is uncontrolled with tamponade, surgical intervention is necessary. The discussion here will cover the standard surgical intervention, while coverage of alternate options will be in the surgical treatment section of this paper.
The standard surgical intervention for the hemodynamically unstable patient is uterine dilatation and curettage (D&C). This procedure can be performed rapidly with decreased bleeding within 1 hour. D&C with hysteroscopy may be more beneficial in identifying a cause for uterine bleeding but is not mandatory. The disadvantage to D&C for acute uterine bleeding is that this procedure will only provide temporary relief. The procedure will not treat the underlying causes, so medical therapy must start upon cessation of uterine bleeding. One study showed that decreased menstrual blood loss was only evident in the first period after the procedure, but subsequently returned to baseline.
For the stable patient, the goal is to control the current bleeding and decrease any future bleeding episodes. The first line treatment for acute abnormal uterine bleeding is hormonal therapy. There are multiple options available, including oral contraceptive pills (OCPs), IV estrogen, medroxyprogesterone acetate, and tranexamic acid.
IV conjugated estrogen is the only FDA specially approved treatment for acute AUB, due to the limited studies. One randomized control study showed that IV conjugated estrogen stopped bleeding for 72% of patients within 8 hours with the majority of those women showing results at 5 hours. The mechanism of action of estrogen therapy is the rapid regrowth of the endometrium over the exposed epithelial surface.
The recommended dose is 25mg IV every 4-6 hours for 24 hours. After 24 hours, the patient should transition to oral combined contraceptive pills or progestin to decrease the unopposed estrogen exposure. The contraindications for IV estrogen are as follows:
Combined oral contraceptive pills and oral progestins are commonly used medications for acute AUB. One study showed that treatment with either medication taken for one week stopped the bleeding in 3 days for 76-88% of women. The recommended treatment regimen for monophasic combined oral contraceptive pills that contain a minimum of 35mcg of ethinylestradiol is three times a day for seven days.Contraindications include:
The treatment regimen for progestins is medroxyprogesterone acetate 20mg orally three times a day for seven days. The contraindications include:
Tranexamic acid received approval for the treatment of AUB in 2009. This drug is an antifibrinolytic that reversibly binds to plasminogen preventing fibrin degradation. The recommended treatment regimen is tranexamic acid 1-1.5g orally every 8 hours for five days or 10mg/kg IV (max dose 600mg/dose) every 8 hours for five days. Contraindications include:
As mentioned previously D&C is the current surgical treatment of choice for acute AUB; however, the other surgical options available to providers are endometrial ablation, uterine artery embolization, and hysterectomy. Endometrial ablation is an effective treatment in women who have contraindications to the medical therapies mentioned above. This procedure should only be performed on women who no longer desire fertility and when the possibility of endometrial or uterine cancer has been ruled out as possible causes of acute AUB. Uterine artery embolization is the first line treatment for women with the rare etiology of uterine bleeding from a uterine arteriovenous malformation. The physician should not use this procedure on the unstable patient since other options are more readily available. A hysterectomy is the last resort procedure and should onlt be used after the patient has failed medical therapy or other surgical interventions.
This paper has already listed the FIGO etiology classification for AUB. The PALM-COEIN classification system list nine different differentials for the provider to consider. This section will cover some additional diagnoses that are important differentials in the emergency department. The uterus is the only organ for which bleeding represents a normal physiologic process, and might mask other etiologies of anemia, especially in peri-menopausal women. The normal menstrual cycle, on average, lasts 4-9 days with a blood loss of less than 80 mL. Molimina symptoms like cramping, mood swings, breast tenderness, and fluid retention precede menstruation. Pregnancy or ectopic pregnancy can often present with vaginal bleeding. All women within the reproductive years should have a pregnancy test as part of their initial workup.
The prognosis of AUB is vastly dependent on the etiology, as classified through the PALM-COEIN system. In women with premenopausal acute uterine bleeding, the prognostic data basis is quality of life; 50% of women presenting with abnormal uterine bleeding present with less than 40mLs of blood loss, meaning that quality of life is driving the decision to seek medical attention. Quality of life testing suggests that women with AUB will score below the 25 percentile against women of similar age. When evaluating, treating, and managing these patients it is important to not only focus on mortality and morbidity, but also the quality of life. The form used in most research studies is the short form 36 health survey, used in 63% of studies in a meta-analysis review regarding AUB.Recently a heavy menstrual bleeding questionnaire was developed to assist in validating patient-reported outcomes. This form covers a range of symptoms, amount of bleeding, social embarrassment, and fear of social interactions because of AUB. ("The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding.")
Acute Uterine Bleeding is a complication that can be emotionally devastating to the patient as well as life-threatening. It is crucial for emergency physicians to involve gynecologists in the management of this disease quickly. The collaborative efforts will ensure a quick resolution to the unstable patient as well as appropriate treatment options for the stable ones. The team approach will not only ensure swift, appropriate care and cessation of the bleeding but will ensure long-term follow-up for prevention of future bleeding episodes. With the team approach to patient care, it allows for a direct transition to the outpatient clinic where discussion and implementation of long-term medical or surgical treatment options can take place.
|||Munro MG,Critchley HO,Broder MS,Fraser IS, FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2011 Apr [PubMed PMID: 21345435]|
|||ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstetrics and gynecology. 2013 Apr [PubMed PMID: 23635706]|
|||Kjerulff KH,Erickson BA,Langenberg PW, Chronic gynecological conditions reported by US women: findings from the National Health Interview Survey, 1984 to 1992. American journal of public health. 1996 Feb [PubMed PMID: 8633735]|
|||Nicholson WK,Ellison SA,Grason H,Powe NR, Patterns of ambulatory care use for gynecologic conditions: A national study. American journal of obstetrics and gynecology. 2001 Mar [PubMed PMID: 11262448]|
|||Warner PE,Critchley HO,Lumsden MA,Campbell-Brown M,Douglas A,Murray GD, Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data. American journal of obstetrics and gynecology. 2004 May [PubMed PMID: 15167821]|
|||Kouides PA,Conard J,Peyvandi F,Lukes A,Kadir R, Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding. Fertility and sterility. 2005 Nov [PubMed PMID: 16275228]|
|||James AH,Kouides PA,Abdul-Kadir R,Dietrich JE,Edlund M,Federici AB,Halimeh S,Kamphuisen PW,Lee CA,Mart�nez-Perez O,McLintock C,Peyvandi F,Philipp C,Wilkinson J,Winikoff R, Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. European journal of obstetrics, gynecology, and reproductive biology. 2011 Oct [PubMed PMID: 21632169]|
|||Haynes PJ,Hodgson H,Anderson AB,Turnbull AC, Measurement of menstrual blood loss in patients complaining of menorrhagia. British journal of obstetrics and gynaecology. 1977 Oct [PubMed PMID: 921913]|
|||DeVore GR,Owens O,Kase N, Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding--a double-blind randomized control study. Obstetrics and gynecology. 1982 Mar [PubMed PMID: 6281704]|
|||Munro MG,Mainor N,Basu R,Brisinger M,Barreda L, Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. Obstetrics and gynecology. 2006 Oct [PubMed PMID: 17012455]|
|||Nichols CM,Gill EJ, Thermal balloon endometrial ablation for management of acute uterine hemorrhage. Obstetrics and gynecology. 2002 Nov [PubMed PMID: 12423817]|
|||Ghai S,Rajan DK,Asch MR,Muradali D,Simons ME,TerBrugge KG, Efficacy of embolization in traumatic uterine vascular malformations. Journal of vascular and interventional radiology : JVIR. 2003 Nov [PubMed PMID: 14605105]|
|||Matteson KA,Boardman LA,Munro MG,Clark MA, Abnormal uterine bleeding: a review of patient-based outcome measures. Fertility and sterility. 2009 Jul [PubMed PMID: 18635169]|
|||Clark TJ,Khan KS,Foon R,Pattison H,Bryan S,Gupta JK, Quality of life instruments in studies of menorrhagia: a systematic review. European journal of obstetrics, gynecology, and reproductive biology. 2002 Sep 10 [PubMed PMID: 12206918]|
|||Matteson KA,Scott DM,Raker CA,Clark MA, The menstrual bleeding questionnaire: development and validation of a comprehensive patient-reported outcome instrument for heavy menstrual bleeding. BJOG : an international journal of obstetrics and gynaecology. 2015 Apr [PubMed PMID: 25615842]|